Targeted Degradation of Phosphorylated p38 MAPK (Tyr182) as a Novel Therapeutic Strategy for Alzheimer’s Disease
22 Apr 2026
by AntBio
Targeted Degradation of Phosphorylated p38 MAPK (Tyr182) as a Novel Therapeutic Strategy for Alzheimer’s Disease
Literature Analysis & Product Highlight
Literature Information
This review summarizes cutting‑edge research on selective degradation of phosphorylated p38 MAPK (Tyr182) as a transformative approach to treat Alzheimer’s disease (AD). The work highlights how PROTAC‑mediated targeted protein degradation reverses core AD pathologies, including neuroinflammation, amyloid‑beta plaque formation, and cognitive decline.
Research Background
Alzheimer’s disease is defined by three pathological hallmarks: amyloid‑beta (Aβ) plaque deposition, neurofibrillary tangles, and chronic neuroinflammation. The stress‑activated kinase p38 MAPK is strongly implicated in disease progression. When phosphorylated at Tyr182, activated p‑p38 drives inflammatory signaling, synaptic dysfunction, and neuronal damage. Traditional kinase inhibitors suffer from poor selectivity or off‑target effects, necessitating new drug design strategies.
Research Approach
The study employed conformation‑selective ligand design to target the unique structural interface exposed upon p38 MAPK phosphorylation at Tyr182. These ligands were conjugated to E3 ubiquitin ligase ligands to generate selective PROTAC molecules. These compounds specifically recruit the ubiquitin‑proteasome system to degrade activated p‑p38 without affecting total p38 levels.
Key Research Outcomes
- Selective PROTACs eliminate phosphorylated p38 MAPK (Tyr182) in the brain without altering endogenous p38.
- Reduced microgliosis, astrogliosis, and pro‑inflammatory cytokine release.
- Diminished Aβ plaque formation and tau hyperphosphorylation.
- Improved synaptic plasticity and significant recovery of learning and memory.
- Demonstrated that conformation‑specific degradation is a viable strategy for neurodegenerative disease intervention.
Product Empowerment by ANTBIO PTE. LTD.
ANTBIO’s Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit Monoclonal Antibody (Cat. S0B0265) is an essential tool for validating this therapeutic mechanism. It enables highly specific detection of activated p38 in Western blot, immunofluorescence, and flow cytometry applications, supporting target validation, pharmacodynamic studies, and translational research.
Brand Mission
ANTBIO PTE. LTD. is committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress.
Related Product List
- Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit mAb (S0B0265)
- p38 MAPK pathway‑related ELISA kits
- Neuroinflammation research antibody panel
ANTBIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are dedicated to empowering researchers worldwide with innovative, high‑quality reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
ANTBIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
